We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2.
- Authors
Parsons, Lauren N.; Mullen, Elizabeth A.; Geller, James I.; Chi, Yueh‐Yun; Khanna, Geetika; Glick, Richard D.; Aldrink, Jennifer H.; Vallance, Kelly L.; Kim, Yeonil; Fernandez, Conrad V.; Dome, Jeffrey S.; Perlman, Elizabeth J.; Chi, Yueh-Yun
- Abstract
<bold>Background: </bold>Stage I epithelial-predominant favorable-histology Wilms tumors (EFHWTs) have long been suspected to have an excellent outcome. This study investigates the clinical and pathologic features of patients with stage I EFHWTs to better evaluate the potential for a reduction of chemotherapy and its associated toxicity.<bold>Methods: </bold>All patients registered in the Children's Oncology Group (COG) AREN03B2 study between 2006 and 2017 with stage I EFHWTs were identified. EFHWTs were defined as tumors with at least 66% epithelial differentiation, regardless of the degree of differentiation. Clinical information was abstracted from COG records. Event-free survival (EFS) and overall survival (OS) were calculated and compared between groups based on age and therapy.<bold>Results: </bold>The 4-year EFS rate was 96.2% (95% confidence interval, 92%-100%), and the OS rate was 100%; EFS and OS did not statistically significantly differ with the age at diagnosis (<48 vs ≥48 months; P = .37) or treatment (EE4A vs observation only; P = .55). Six events were reported. Three patients developed contralateral tumors and did not otherwise relapse; none of these had nephrogenic rests or a recognized predisposition syndrome. Three patients developed metastatic recurrence; all 3 had received EE4A as their primary therapy after nephrectomy.<bold>Conclusions: </bold>These findings demonstrate an excellent outcome for stage I EFHWTs with >95% EFS and OS. These data support the utility of investigating the treatment of stage I EFHWTs with observation alone after nephrectomy.
- Subjects
NEPHROBLASTOMA; ONCOLOGY; AGE groups; CHILD patients; REDUCTION potential; THERAPEUTIC use of antineoplastic agents; NEPHRECTOMY; CANCER relapse; RETROSPECTIVE studies; PROGNOSIS; KIDNEY tumors; RESEARCH funding; EPITHELIAL cells
- Publication
Cancer (0008543X), 2020, Vol 126, Issue 12, p2866
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/cncr.32855